GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (LTS:0IRF) » Definitions » Cyclically Adjusted PS Ratio

Evotec SE (LTS:0IRF) Cyclically Adjusted PS Ratio : 1.95 (As of Jun. 03, 2025)


View and export this data going back to 2009. Start your Free Trial

What is Evotec SE Cyclically Adjusted PS Ratio?

As of today (2025-06-03), Evotec SE's current share price is €6.771. Evotec SE's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €3.48. Evotec SE's Cyclically Adjusted PS Ratio for today is 1.95.

The historical rank and industry rank for Evotec SE's Cyclically Adjusted PS Ratio or its related term are showing as below:

LTS:0IRF' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.54   Med: 15.72   Max: 25.76
Current: 1.97

During the past years, Evotec SE's highest Cyclically Adjusted PS Ratio was 25.76. The lowest was 1.54. And the median was 15.72.

LTS:0IRF's Cyclically Adjusted PS Ratio is ranked better than
52.57% of 738 companies
in the Drug Manufacturers industry
Industry Median: 2.13 vs LTS:0IRF: 1.97

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Evotec SE's adjusted revenue per share data for the three months ended in Mar. 2025 was €1.126. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €3.48 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Evotec SE Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Evotec SE's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Cyclically Adjusted PS Ratio Chart

Evotec SE Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.93 21.58 6.18 7.29 2.44

Evotec SE Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.75 2.85 1.98 2.44 1.75

Competitive Comparison of Evotec SE's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Evotec SE's Cyclically Adjusted PS Ratio falls into.


;
;

Evotec SE Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Evotec SE's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=6.771/3.48
=1.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evotec SE's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Evotec SE's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.126/127.7792*127.7792
=1.126

Current CPI (Mar. 2025) = 127.7792.

Evotec SE Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.254 100.417 0.323
201509 0.253 100.417 0.322
201512 0.253 99.717 0.324
201603 0.283 100.017 0.362
201606 0.287 100.717 0.364
201609 0.341 101.017 0.431
201612 0.331 101.217 0.418
201703 0.364 101.417 0.459
201706 0.365 102.117 0.457
201709 0.462 102.717 0.575
201712 0.626 102.617 0.779
201803 0.554 102.917 0.688
201806 0.660 104.017 0.811
201809 0.673 104.718 0.821
201812 0.657 104.217 0.806
201903 0.696 104.217 0.853
201906 0.690 105.718 0.834
201909 0.763 106.018 0.920
201912 0.832 105.818 1.005
202003 0.791 105.718 0.956
202006 0.739 106.618 0.886
202009 0.857 105.818 1.035
202012 0.868 105.518 1.051
202103 0.811 107.518 0.964
202106 0.841 108.486 0.991
202109 0.970 109.435 1.133
202112 1.083 110.384 1.254
202203 0.932 113.968 1.045
202206 0.975 115.760 1.076
202209 0.984 118.818 1.058
202212 1.363 119.345 1.459
202303 1.207 122.402 1.260
202306 0.962 123.140 0.998
202309 1.109 124.195 1.141
202312 1.136 123.773 1.173
202403 1.177 125.038 1.203
202406 1.027 125.882 1.042
202409 1.043 126.198 1.056
202412 1.246 127.041 1.253
202503 1.126 127.779 1.126

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evotec SE  (LTS:0IRF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Evotec SE Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Evotec SE's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE Business Description

Industry
Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Evotec SE Headlines

No Headlines